

In the specification:

Please amend paragraph [0215] of the specification as follows:

[0215] The results of this study and our previous work (Gallegos, A. et al., Cancer Res., 56:5765-5770, 1996) suggest that the Trx system offers a novel target for agents to promote apoptosis and inhibit tumor growth, as well as to reverse the drug resistance of some cancers. It is interesting, therefore, that some 2-imidazolyl disulfide inhibitors of Trx (Kuperus, M. et al., Proc. Am. Assoc. Cancer Res., 36:426, 1995) have been shown to induce apoptosis in cancer cells (~~Powis, G. et al., Anticancer Drugs, 7 (Suppl. 3):121-126, 1996~~) and, in animal studies by intraperitoneal and oral administration, to have antitumor effects. In particular, 1-methylpropyl-2-imidazolyl disulfide exhibits dose-dependant antitumor activity in mice. Oral administration of 1-methylpropyl-2-imidazolyl disulfide in the diet of mice at up to 250 ppm, reduces the number of tumors in the colon by 70%, and causes a significant reduction in the size of the remaining tumors. Injection of mice with 1-methylpropyl-2-imidazolyl disulfide at 5mg/kg, 10mg/kg, and 15mg/kg reduces the volume of tumors significantly (Powis, G. et al., Anticancer Drugs, 7 (Suppl. 3):121-126, 1996).